Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Akebia Therapeutics (AKBA) Misses Q1 EPS by 16c, Revenues Miss
May 10, 2021 8:10 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.45), $0.16 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $55.72 million.
"Akebia is off to a great start in 2021, building positive momentum with solid execution on strategic priorities that set the stage for an... More
